Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial

被引：0
|
作者：
Chan, A. [1 ]
Ganju, V. [2 ]
Becquart, D. [3 ]
Conte, P. F. [4 ]
Petruzelka, L. [5 ]
Perrot, O. [6 ]
Villanova, G. [6 ]
Tubiana-Mathieu, N. [7 ]
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Frankston Hosp, Frankston, Australia
[3] AZ Middlelheim, Antwerp, Belgium
[4] Policlin Modena, Modena, Italy
[5] Gen Teaching Hosp, Prague, Czech Republic
[6] Inst Rech Pierre Fabre, Boulogne, France
[7] CHU Dupuytren, Limoges, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70886-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2124
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [21] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [22] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
  • [23] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [24] A Phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)
    Xu, L.
    Song, S.
    Zhu, J.
    Lu, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
  • [25] ACTIVITY AND SAFETY OF THREE-WEEKLY TRASTUZUMAB (T) PLUS AN ALL-ORAL COMBINATION OF VINORELBINE (VNR) AND CAPECITABINE (CAP) AS FIRST-LINE TREATMENT IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): A PROSPECTIVE PHASE II STUDY
    Palumbo, Raffaella
    Bernardo, Antonio
    Strada, Maria Rosa
    Poggi, Guido
    Teragni, Cristina
    Amatu, Alessio
    Montagna, Benedetta
    Tagliaferri, Barbara
    Sottotetti, Federico
    Frascaroli, Mara
    Bernardo, Giovanni
    ANNALS OF ONCOLOGY, 2009, 20
  • [26] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [27] Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial)
    Amoroso, D.
    Donati, S.
    Valsuani, C.
    Puccetti, C.
    Rondini, M.
    Siclari, O.
    Tartarelli, G.
    Giannessi, P.
    Falcone, A.
    Camerini, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Petruzelka, L.
    Gil-Gil, M.
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    Tubiana-Mathieu, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 277
  • [29] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N. U. Lin
    D. S. Seah
    R. Gelman
    S. Desantis
    E. L. Mayer
    S. Isakoff
    P. DiPiro
    I. E. Krop
    S. E. Come
    D. Weckstein
    E. P. Winer
    H. J. Burstein
    Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
  • [30] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    Lin, N. U.
    Seah, D. S.
    Gelman, R.
    Desantis, S.
    Mayer, E. L.
    Isakoff, S.
    DiPiro, P.
    Krop, I. E.
    Come, S. E.
    Weckstein, D.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
12345